-
2
-
-
33845341470
-
Impact of recent increase in incidence on future diabetes burden: U.S. 2005-2050
-
Narayan K., Boyle J., Geiss L., et al. Impact of recent increase in incidence on future diabetes burden: U.S. 2005-2050. Diabetes Care 29 (2006) 2114-2116
-
(2006)
Diabetes Care
, vol.29
, pp. 2114-2116
-
-
Narayan, K.1
Boyle, J.2
Geiss, L.3
-
3
-
-
41849148860
-
-
National Diabetes Surveillance System. Diabetes data and trends: age-adjusted percentage of adults with diabetes using diabetes medication, by type of medication, United States, 1997-2003. Centers for Disease Control and Prevention Accessed October 15, 2007
-
National Diabetes Surveillance System. Diabetes data and trends: age-adjusted percentage of adults with diabetes using diabetes medication, by type of medication, United States, 1997-2003. Centers for Disease Control and Prevention. http://www.cdc.gov/diabetes/statistics/meduse/fig2.htm Accessed October 15, 2007
-
-
-
-
4
-
-
33744968835
-
Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey
-
Resnick H., Foster G., Bardsley J., and Ratner R. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care 29 (2006) 531-537
-
(2006)
Diabetes Care
, vol.29
, pp. 531-537
-
-
Resnick, H.1
Foster, G.2
Bardsley, J.3
Ratner, R.4
-
5
-
-
0036736185
-
When oral agents fail: practical barriers to starting insulin
-
Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 26 Suppl 3 (2002) S18-S24
-
(2002)
Int J Obes Relat Metab Disord
, vol.26
, Issue.SUPPL. 3
-
-
Korytkowski, M.1
-
6
-
-
41849117551
-
A regular human insulin formulation with a more rapid onset of action than rapid-acting insulin analogues
-
Accessed October 15, 2007
-
Steiner S., Hompesch M., Pohl R., and Simms P. A regular human insulin formulation with a more rapid onset of action than rapid-acting insulin analogues. Insulin Congress Abstracts: The Evolving Science and Practice of Insulin Therapy 2 Suppl A (2007) S21. http://www.insulinjournal.com/Images/pdfs/Insulin_s2_11_Other.pdf Accessed October 15, 2007
-
(2007)
Insulin Congress Abstracts: The Evolving Science and Practice of Insulin Therapy
, vol.2
, Issue.SUPPL. A
-
-
Steiner, S.1
Hompesch, M.2
Pohl, R.3
Simms, P.4
-
7
-
-
41849150285
-
Intra-dermal insulin lispro application with a new microneedle delivery system led to a substantially more rapid insulin absorption than subcutaneous injection: P909
-
Heinemann L., Hompesch M., Kapitza C., et al. Intra-dermal insulin lispro application with a new microneedle delivery system led to a substantially more rapid insulin absorption than subcutaneous injection: P909. Diabetic Med 23 Suppl 4 (2006) 329
-
(2006)
Diabetic Med
, vol.23
, Issue.SUPPL. 4
, pp. 329
-
-
Heinemann, L.1
Hompesch, M.2
Kapitza, C.3
-
8
-
-
1042291852
-
Concept, strategies, and feasibility of noninvasive insulin delivery
-
Cefalu W. Concept, strategies, and feasibility of noninvasive insulin delivery. Diabetes Care 27 (2004) 239-246
-
(2004)
Diabetes Care
, vol.27
, pp. 239-246
-
-
Cefalu, W.1
-
9
-
-
0023131817
-
On the way to the automated (blood) glucose regulation in diabetes: the dark past, the grey present and the rosy future. XII Congress of the International Diabetes Federation, Madrid, Spain, 1985
-
Pfeiffer E. On the way to the automated (blood) glucose regulation in diabetes: the dark past, the grey present and the rosy future. XII Congress of the International Diabetes Federation, Madrid, Spain, 1985. Diabetologia 30 (1987) 51-65
-
(1987)
Diabetologia
, vol.30
, pp. 51-65
-
-
Pfeiffer, E.1
-
10
-
-
11844250564
-
Insulin analogues
-
Hirsch I. Insulin analogues. N Engl J Med 352 (2005) 174-183
-
(2005)
N Engl J Med
, vol.352
, pp. 174-183
-
-
Hirsch, I.1
-
11
-
-
42749106543
-
Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus
-
Apr 19:CD003287
-
Siebenhofer A., Plank J., Berghold A., et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev (2006) Apr 19:CD003287
-
(2006)
Cochrane Database Syst Rev
-
-
Siebenhofer, A.1
Plank, J.2
Berghold, A.3
-
12
-
-
22144484165
-
Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus
-
Plank J., Siebenhofer A., Berghold A., et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 165 (2005) 1337-1344
-
(2005)
Arch Intern Med
, vol.165
, pp. 1337-1344
-
-
Plank, J.1
Siebenhofer, A.2
Berghold, A.3
-
13
-
-
31844437604
-
Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study
-
Martin S., Schneider B., Heinemann L., et al. Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia 49 (2006) 271-278
-
(2006)
Diabetologia
, vol.49
, pp. 271-278
-
-
Martin, S.1
Schneider, B.2
Heinemann, L.3
-
14
-
-
41849145925
-
Pharmacodynamic properties of Viaject™: a novel rapid acting regular human insulin
-
#A139
-
Steiner S., Hompesch M., Pohl R., et al. Pharmacodynamic properties of Viaject™: a novel rapid acting regular human insulin. Biodel Inc., Danbury, Conn, and Profil Institute for Clinical Research, Chula Vista, Calif. Fifth Annual Diabetes Technology Meeting, San Francisco, Calif (2005) #A139
-
(2005)
Biodel Inc., Danbury, Conn, and Profil Institute for Clinical Research, Chula Vista, Calif. Fifth Annual Diabetes Technology Meeting, San Francisco, Calif
-
-
Steiner, S.1
Hompesch, M.2
Pohl, R.3
-
15
-
-
41849122554
-
-
Biodel Inc. announces VIAject™ data at oral presentation at the American Diabetes Association meeting [press release]. Biodel Inc., Danbury Conn; June 22, 2007 Accessed October 15, 2007
-
Biodel Inc. announces VIAject™ data at oral presentation at the American Diabetes Association meeting [press release]. Biodel Inc., Danbury Conn; June 22, 2007. http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/sto ry/06-22-2007/0004613899&EDATE= Accessed October 15, 2007
-
-
-
-
16
-
-
0035349026
-
Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients
-
Rave K., Heise T., Pfützner A., et al. Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care 24 (2001) 886-890
-
(2001)
Diabetes Care
, vol.24
, pp. 886-890
-
-
Rave, K.1
Heise, T.2
Pfützner, A.3
-
17
-
-
34547879624
-
Insulin glulisine: a faster onset of action compared with insulin lispro
-
Heise T., Nosek L., Spitzer H., et al. Insulin glulisine: a faster onset of action compared with insulin lispro. Diabetes Obes Metab 9 (2007) 746-753
-
(2007)
Diabetes Obes Metab
, vol.9
, pp. 746-753
-
-
Heise, T.1
Nosek, L.2
Spitzer, H.3
-
18
-
-
25644437167
-
Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro
-
Rave K., Nosek L., de la Pena A., et al. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. Diabetes Care 28 (2005) 2400-2405
-
(2005)
Diabetes Care
, vol.28
, pp. 2400-2405
-
-
Rave, K.1
Nosek, L.2
de la Pena, A.3
-
19
-
-
18144368866
-
Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin
-
Rave K., Bott S., Heinemann L., et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 28 (2005) 1077-1082
-
(2005)
Diabetes Care
, vol.28
, pp. 1077-1082
-
-
Rave, K.1
Bott, S.2
Heinemann, L.3
-
20
-
-
0036025088
-
Technosphere/Insulin-a new approach for effective delivery of human insulin via the pulmonary route
-
Pfützner A., Mann A., and Steiner S. Technosphere/Insulin-a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol Ther 4 (2002) 589-594
-
(2002)
Diabetes Technol Ther
, vol.4
, pp. 589-594
-
-
Pfützner, A.1
Mann, A.2
Steiner, S.3
-
21
-
-
33748765784
-
®) improve management of type 2 diabetes? The design of the Real World trial
-
for the Real World Trialists Accessed October 15, 2007
-
®) improve management of type 2 diabetes? The design of the Real World trial. Trials 7 (2006) 25. http://www.trialsjournal.com/content/7/1/25 Accessed October 15, 2007
-
(2006)
Trials
, vol.7
, pp. 25
-
-
Freemantle, N.1
Strack, T.2
-
22
-
-
16844382684
-
Oral delivery of insulin with the eligen technology: mechanistic studies
-
Malkov D., Angelo R., Wang H., et al. Oral delivery of insulin with the eligen technology: mechanistic studies. Curr Drug Deliv 2 (2005) 191-197
-
(2005)
Curr Drug Deliv
, vol.2
, pp. 191-197
-
-
Malkov, D.1
Angelo, R.2
Wang, H.3
-
23
-
-
11144254615
-
Oral spray insulin in treatment of type 2 dia-betes: a comparison of efficacy of the oral spray insulin (Oralin) with subcutaneous (SC) insulin injection, a proof of concept study
-
Guevara-Aguirre J., Guevara M., Saavedra J., et al. Oral spray insulin in treatment of type 2 dia-betes: a comparison of efficacy of the oral spray insulin (Oralin) with subcutaneous (SC) insulin injection, a proof of concept study. Diabetes Metab Res Rev 20 (2004) 472-478
-
(2004)
Diabetes Metab Res Rev
, vol.20
, pp. 472-478
-
-
Guevara-Aguirre, J.1
Guevara, M.2
Saavedra, J.3
-
24
-
-
0023244003
-
Effects of intranasal insulin in non-obese type II diabetics
-
Frauman A., Jerums G., and Louis W. Effects of intranasal insulin in non-obese type II diabetics. Diabetes Res Clin Pract 3 (1987) 197-202
-
(1987)
Diabetes Res Clin Pract
, vol.3
, pp. 197-202
-
-
Frauman, A.1
Jerums, G.2
Louis, W.3
-
25
-
-
0021918027
-
Intranasal aerosolized insulin Mixed-meal studies and long-term use in type I diabetes
-
Salzman R., Manson J., Griffing G., et al. Intranasal aerosolized insulin Mixed-meal studies and long-term use in type I diabetes. N Engl J Med 312 (1985) 1078-1084
-
(1985)
N Engl J Med
, vol.312
, pp. 1078-1084
-
-
Salzman, R.1
Manson, J.2
Griffing, G.3
-
26
-
-
0034845659
-
Efficacy and tolerance of intranasal insulin administered during 4 months in severely hyperglycaemic type 2 diabetic patients with oral drug failure: a cross-over study
-
Lalej-Bennis D., Boillot J., Bardin C., et al. Efficacy and tolerance of intranasal insulin administered during 4 months in severely hyperglycaemic type 2 diabetic patients with oral drug failure: a cross-over study. Diabet Med 18 (2001) 614-618
-
(2001)
Diabet Med
, vol.18
, pp. 614-618
-
-
Lalej-Bennis, D.1
Boillot, J.2
Bardin, C.3
-
27
-
-
0034942194
-
Six month administration of gelified intranasal insulin in 16 type 1 diabetic patients under multiple injections: efficacy vs subcutaneous injections and local tolerance
-
Lalej-Bennis D., Boillot J., Bardin C., et al. Six month administration of gelified intranasal insulin in 16 type 1 diabetic patients under multiple injections: efficacy vs subcutaneous injections and local tolerance. Diabet Metab 27 (2001) 372-377
-
(2001)
Diabet Metab
, vol.27
, pp. 372-377
-
-
Lalej-Bennis, D.1
Boillot, J.2
Bardin, C.3
-
28
-
-
0028967620
-
Intranasal insulin: the effects of three dose regimens on postprandial glycaemic profiles in type II diabetic subjects
-
Coates P., Ismail I., Luzio S., et al. Intranasal insulin: the effects of three dose regimens on postprandial glycaemic profiles in type II diabetic subjects. Diabet Med 12 (1995) 235-239
-
(1995)
Diabet Med
, vol.12
, pp. 235-239
-
-
Coates, P.1
Ismail, I.2
Luzio, S.3
-
29
-
-
41849100239
-
-
TransPharma Medical. The insulin human clinical trial Accessed October 15, 2007
-
TransPharma Medical. The insulin human clinical trial. http://www.transpharmamedical.com/product_apps_insulin_clinical_trial.ht ml Accessed October 15, 2007
-
-
-
-
30
-
-
34147147578
-
Implantable insulin pumps. A position statement about their clinical use
-
for the EVADIAC Group
-
Renard E., Schaepelynck-Bélicar P., and for the EVADIAC Group. Implantable insulin pumps. A position statement about their clinical use. Diabetes Metab 33 (2007) 158-166
-
(2007)
Diabetes Metab
, vol.33
, pp. 158-166
-
-
Renard, E.1
Schaepelynck-Bélicar, P.2
-
31
-
-
33750595378
-
Are insulin pumps underutilized in type 1 diabetes? No
-
Schade D., and Valentine V. Are insulin pumps underutilized in type 1 diabetes? No. Diabetes Care 29 (2006) 1453-1455
-
(2006)
Diabetes Care
, vol.29
, pp. 1453-1455
-
-
Schade, D.1
Valentine, V.2
-
32
-
-
33746417553
-
Are insulin pumps underutilized in type 1 diabetes? Yes
-
Pickup J. Are insulin pumps underutilized in type 1 diabetes? Yes. Diabetes Care 29 (2006) 1449-1452
-
(2006)
Diabetes Care
, vol.29
, pp. 1449-1452
-
-
Pickup, J.1
-
33
-
-
33845340831
-
OmniPod Insulin Management System: patient perceptions, preference, and glycemic control
-
Zisser H., and Jovanovic L. OmniPod Insulin Management System: patient perceptions, preference, and glycemic control. Diabetes Care 29 (2006) 2175
-
(2006)
Diabetes Care
, vol.29
, pp. 2175
-
-
Zisser, H.1
Jovanovic, L.2
|